India covid-19 India

Hetero Labs gets DGCI nod to make Gilead's remdesivir for COVID-19 treatment

Reading now: 623
www.livemint.com

₹5,000 to 6,000 for a 100 milligram dose, Hetero said BENGALURU : India's drug regulator has given Hetero Labs the green light to manufacture and market its generic version of Gilead Science's experimental COVID-19 treatment remdesivir, the Indian pharmaceutical company said on Sunday.The drug, which will be marketed under the brand name Covifor, will likely be priced at ₹5,000 to 6,000 ($66-$79) for a 100 milligram dose, Hetero said.India's Cipla Ltd has also received approval from the Drug Controller General of India (DGCI) to manufacture and market the drug, according to a media report.

Cipla and DGCI were not immediately available for comment.Gilead Sciences Inc signed non-exclusive licensing pacts last month with five generic.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA